Locations:

Cancer

September 27, 2019/Cancer/Radiation Oncology

Automated Screening Reduces Errors in Radiation Treatment Planning

Prospective review of parameters improves plan consistency, saves time

September 19, 2019/Cancer/Research

Metabolic Reprogramming: A Promising Approach to Tackling Therapeutic Resistance in Glioblastoma

Targeting pyrimidine synthesis inhibits GSC self-renewal and tumorigenesis

September 18, 2019/Cancer

Stereotactic Body Radiation Therapy: A Promising Approach for Pediatric Patients

Positive outcomes reported for metastatic sarcomas

September 18, 2019/Cancer/Research

Preoperative Pelvic Radiation is Safe, Effective in Patients with IBD and Rectal Cancer

Study affirms XRT’s utility

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

September 17, 2019/Cancer/Research

Postprostatectomy Prostate-Specific Antigen Kinetics Associated with Recurrence After Salvage Radiation

Relapse more likely with faster PSA doubling time

19-NEU-3925-stereotactic-radiosurgery-brain-mets-650×450

September 16, 2019/Cancer

High-Dose Neoadjuvant Radiosurgery for Brain Metastases Appears Safe, Effective in Early Results from Phase 1/2 Study

Dose-escalation trial shows local control with low toxicity, low leptomeningeal recurrence

September 11, 2019/Cancer

Early Identification and Management of Pediatric Patients with Malignancy at Increased Cardiovascular Risk

Involving a pediatric cardio-oncologist early in the treatment of pediatric malignancies

September 11, 2019/Cancer/Research

Catch These Cleveland Clinic Cancer Center Presentations at ASTRO 2019

Join our staff at these oral and poster sessions Sept. 15-18

September 6, 2019/Cancer

Does Endoscopist Specialty Affect Colonoscopy Quality Outcomes?

Cleveland Clinic study finds that both gastroenterologists and colorectal surgeons meet quality benchmarks

September 4, 2019/Cancer/Research

Inotuzumab Ozogamicin Proves Superior to Standard Chemotherapy for Relapsed/Refractory ALL in a Long-Term Follow-up Study

Two-year follow-up confirms initial findings of the INO-VATE trial

BackPage 54 of 140Next